Reduced fixed dose tocilizumab 400 mg IV compared to weight-based dosing in critically ill patients with COVID-19: A before-after cohort study

• প্রধান লেখক: Sophie Stukas (লেখক), George Goshua (লেখক), Angus Kinkade (লেখক), Rebecca Grey (লেখক), Gregory Mah (লেখক), Catherine M. Biggs (লেখক), Shahin Jamal (লেখক), Sonny Thiara (লেখক), Tim T.Y. Lau (লেখক), Jolanta Piszczek (লেখক), Nilu Partovi (লেখক), David D Sweet (লেখক), Agnes Y.Y. Lee (লেখক), Cheryl L. Wellington (লেখক), Mypinder S. Sekhon (লেখক), Luke Y.C. Chen (লেখক)
• বিন্যাস: গ্রন্থ
• প্রকাশিত: Elsevier, 2022-07-01T00:00:00Z.
• বিষয়গুলি: article
• অনলাইন ব্যবহার করুন: Connect to this object online.

Summary: Background: Interleukin-6 inhibitors reduce mortality in severe COVID-19. British Columbia began using tocilizumab 8 mg/kg (maximum 800 mg) in January 2021 in critically ill patients with COVID-19, but due to drug shortages, decreased dosing to 400 mg IV fixed dose in April 2021. The aims o...